Objective assessment of “cardioprotective” efficacy as a prognostic guide to management of mildly symptomatic revascularizable coronary artery disease  by Lim, Richard et al.
1140 JACC Vol. 26, No. 5 
November 1,1995:1140-5 
Objective Assessment of "Cardioprotective" Efficacy as a Prognostic 
Guide to Management of Mildly Symptomatic Revascularizable 
Coronary Artery Disease 
RICHARD L IM,  MD,  MPHxe, MRCP,  LORRAINE DYKE,  
DUNCAN S. DYMOND,  MD,  FRCP,  FACC 
London, England, United Kingdom 
Objectives. The concept of "cardioprotection" based on ejection 
fraction was tested to see whether patients with coronary artery 
disease in whom medical treatment fails to be cardioprotective 
can be distinguished from those in whom it is safe to continue 
such treatment. 
Background. Ejection fraction is of fundamental prognostic 
importance. Its modification by anti-ischemic medication may 
allow assessment of cardioprotection from adverse outcome. 
Methods. Exercise ejection fraction and the change in ejection 
fraction from rest to exercise were measured by radionuclide 
ventriculography with and without background medication i  102 
mildly symptomatic patients with coronary artery disease suitable 
for revascularization but initially treated medically. 
Results. Over 20 months, 23 patients experienced an adverse 
event. With medication, exercise ejection fraction increased 
in patients with and without events. By contrast, the ejection 
fraction response to exercise improved significantly in the event- 
free group only; the group with events had a persistent decrease in 
ejection fraction. By Cox analysis, the ejection fraction response to 
exercise performed with medication made the most significant 
independent contribution to event-free survival. Comparison of 
areas under receiver operating characteristic curves suggested 
that this index is the most useful clinical measure of cardiopro. 
tection. 
Conclusions. An exercise-induced decrease in ejection fraction 
despite antMschemic medication implies failure of cardioprotec- 
tion and a greater short-term risk of adverse outcome and 
crossover to revascularization in patients initially treated medi- 
cally. Conversely, a preserved left ventricular performance onfers 
a satisfactory prognosis while continuing with that treatment. 
Thus, the effect of medication on the ejection fraction response to 
exercise---a reasonable stimate of its cardioprotective efficacy-- 
may influence the choke of continuing with such treatment or 
performing early revascularization. 
(J Am CoU Cardiol 1995;26:1140-5) 
Left ventricular ejection fraction is of fundamental prognostic 
importance in coronary artery disease. During exercise radio- 
nuclide ventriculography, an ejection fraction response that is 
abnormal despite clinically effective background anti-ischemic 
medication may imply continuing vulnerability and a higher 
risk for both adverse cardiac outcome as well as a need for 
revascularization. Conversely, some measure of "cardioprotec- 
tire" efficacy may be inferred from a satisfactory result during 
testing while the subject is receiving medication (1). Accord- 
ingly, patients who were initially treated medically after under- 
going coronary angiography were studied to see whether it is 
possible to distinguish patients in whom such treatment is not 
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cardioprotective from those in whom it can be safely contin- 
ued. 
Methods  
Study patients. Patients at this tertiary referral center 
undergoing coronary angiography specifically for suspected or 
known ischemic heart disease were screened for this prospec- 
tive study, which was approved by the institutional research 
board. In our practice, such patients are already highly selected 
for angiography with a view to revascularization because of 
clinical presentation and, usually, abnormal findings on an 
exercise lectrocardiogram (ECG). We excluded patients be- 
ing investigated because of arrhythmias, valvular disease or 
heart failure, those with previous revascularization a d those 
with significant left main stem coronary artery disease, proxi- 
mal three-vessel or proximal two-vessel disease including the 
left anterior descending artery, insignificant disease or disease 
not suitable for revascularization, estimated angiographic ejec- 
tion fraction <20% or prognostically important noncardiac 
conditions. 
Of 739 patients who were potentially eligible at review of 
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the angiographic data, 637 were duly recommended to undergo 
early revascularization. Thus, 102 patients (mean age 55 years 
[range 31 to 73]; 87 men) gave informed consent to enter this 
study on the basis that 1) although all had disease suitable for 
revascularization (defined visually as ->50% lumen stenosis in 
at least one major noninfarcted picardial artery), 2) none was 
considered tohave significant symptoms (Canadian Cardiovas- 
cular Society class III or worse) or critical patterns of disease 
requiring early revascularization, and so 3) all were initially 
treated medically. Ejection fraction at rest was significantly 
reduced (<40%) in 18 of 87 patients with single- or double- 
vessel disease, and in 7 of 15 patients with triple-vessel disease. 
None of these 15 patients had disease involving the proximal 
left anterior descending artery. 
Anti-ischemic medications. The choice and dosage of con- 
ventional agents were not predetermined but were based on 
individual patient and physician preference. Where necessary, 
treatment was adjusted to render angina no worse than class II 
in the 4 weeks before baseline radionuclide ventriculography. 
Sixty-two patients were being treated with one drug, 26 with 
two drugs and 14 with three drugs. A beta-adrenergic blocking 
agent was used in 55 patients, a calcium channel antagonist in
61 and a long-acting nitrate in 40. Aspirin was used routinely. 
Exercise radiouuclide ventriculography. The cardioprotec- 
tive efficacy of background anti-ischemic medication was as- 
sessed objectively by using first-pass exercise radionuclide 
ventriculography (Scinticor Inc). This study was performed as 
previously described (2), initially while the patient was receiv- 
ing no medication 6 weeks after coronary angiography, and 
again 4 weeks later after resumption of medication. The total 
amount of radioactivity administered (effective dose 8 roSy) 
was judged to be safe by the local radiation protection adviser. 
Testing in the absence of medication required withdrawal of all 
regular anti-ischemic medications (except aspirin and sublin- 
gual nitroglycerin) for 3 days before the day of the test. 
For both tests, exercise was symptom-limited with no 
requirement for uniformity of duration or work load. Patients 
acted as their own controls. ST segment monitoring was not 
employed routinely in our laboratory. The prognostic indexes 
of principal interest were the peak exercise jection fraction 
and the change in ejection fraction from rest to exercise. The 
physicians primarily responsible for the patients had no knowl- 
edge of these measurements. 
In one patient, the initial test in the absence of medication 
could not be scheduled early enough; three other patients did 
not undergo testing because of equipment failure. One patient 
died before his test with medication. At baseline, three patients 
had a normal exercise ejection fraction (->50%) and an 
increase in ejection fraction with exercise and thus did not 
proceed to retesting with medication. 
Follow-up. Telephone contact was made at 3-monthly in- 
tervals until the study was terminated at 20 months or an 
adverse vent occurred. The following events constituted end 
points: cardiac death, myocardial infarction, revascularization 
for significant breakthrough symptoms, and unstable angina 
necessitating hospital admission. 
Statistical analysis. Receiver operating characteristic plots 
of sensitivity/(1-specificity) (3) were constructed from the 
entire range of observed values for exercise jection fraction 
and the change in ejection fraction from rest to exercise both 
without and with medication. The best cutoff point for predict- 
ing adverse outcome was that which maximized the sum of the 
sensitivity and specificity, that is, the point nearest the top left 
corner of the receiver operating characteristic curve. Using the 
respective cutoff point, the cohort was separated into two 
groups and a Kaplan-Meier event-free survival curve was 
generated for each radionuclide index without and with med- 
ication. The Lee-Desu log rank test (SSPS/PC + version 4.0) 
was used to compare vent-free survival in these two groups; 
the hazard ratio was derived to express the relative event-free 
survival rates. 
As a measure of how well the radionuclide indexes discrim- 
inated between patients with and without adverse vents, the 
areas under the respective receiver operating characteristic 
curves were calculated (4) and compared (Metz CLABROC 
version 1.2.2). An area under the curve of 1.0 corresponds to 
perfect discrimination, whereas 0.5 indicates no discrimination. 
To determine whether the most highly discriminant index was 
still associated with event-free survival after adjusting for other 
baseline variables (age, positive exercise ECG, three-vessel 
disease, rest ejection fraction on medication, maximal exercise 
work load on medication), a Cox proportional hazards model 
(SAS version 6.07) (5) was fitted by using a forward stepwise 
selection of variables if they were significant at the 5% level. 
To assess whether testing the cardioprotectiveness of med- 
ication provided prognostic information beyond that contained 
in testing in the absence of medication, exercise ejection 
fraction with medication and the change in ejection fraction 
from rest to exercise with medication were considered for entry 
into a forward stepwise logistic regression model into which 
the two corresponding variables without medication had al- 
ready been forced. 
Resu l ts  
Adverse events. By the end of the study, 23 patients had 
had an adverse vent (fatal myocardial infarction in 2, nonfatal 
infarction in 3, coronary bypass urgery in 6 and angioplasty in
4 for troublesome breakthrough symptoms, and unstable an- 
gina requiring hospital admission in 8). 
One of the two deaths (in a patient with disease of the left 
circumflex and right coronary arteries) occurred before radio- 
nuclide ventriculography could be repeated with medication. 
The other patient also had two-vessel disease (left anterior 
descending and right coronary arteries). Without medication, 
he had an absolute exercise-induced decrease in ejection 
fraction of 44% (ejection fraction 79% at rest, 35% during 
exercise). With medication (beta-blocker), there was a persis- 
tent, albeit smaller, exercise-induced decrease of 16% (ejection 
fraction 60% at rest, 44% during exercise). He remained 
asymptomatic until angina recurred at 13 months and he had a 
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Table 1. Comparison tGroups With and Without Adverse Events 
No Events (n = 79) Events (n = 23) p Value 
Mean Difference 
Between Groups 
(95% CI) 
Age (yr) 55 (32 to 73; 9) 54 131 to 67; 9) 0.61 -3  to +5 
Beta-blocker 4 l 14 0.45 -22 to + 10 
3-vessel CAD 11 4 0.68 -29 to +19 
Without medication 
Rest LVEF (c~) 5t) (211 to 78; 13) 48 (23 to 79; 14) 0.59 -5  to +9 
Exercise LVEF (%) 46 118 to 72; 13) 36 (21 to 56; 9) 0.0005 4 to 14 
ALVEI-15';) 4( 251o +18;8) 11 ( 44to +9; 10) 0.0064 2to 12 
With medication 
Rest LVEF ( ' i )  49 (18 to 72: 13) 51 (28 to 67; 12) 0.45 -8  to +4 
Exercise LVEF ('~) 51 (17 to 86; 13) 43 (22 to 59; 11) 0.0057 3 to 14 
ALVEF (~f) +2 ( 18 to +32; 9) 8 ( 25 to ~7; 8) 0.0000 6 to 15 
Work load (kg-m/min) 757 (4111) to 1,20t1: 168) 691 (401) to 1,000; 169) 0.12 -17 to +149 
Data ate expressed as mean value (range; SD). CAD = coronary artery disease; CI = confidence interval; 
ALVEF = change in left ventricular ejection fraction from rest to exercise: LVEF = left ventricular ejection fraction. 
fatal anterior infarction just before urgently scheduled repeat 
coronary angiography could be performed. 
The groups with and without adverse vents were similar 
with respect o mean age, mean rest ejection fraction, the 
proportion receiving beta-blocker therapy and the proportion 
with three-vessel disease. (Table 1). However, the group with 
events had a lower mean exercise jection fraction and greater 
exercise-induced decrease in ejection fraction than did the 
event-free group, whether adionuclide ventriculography was 
performed without or with medication. 
Effect of medication on ejection fraction response to exer- 
cise. During radionuclide ventriculography performed with 
medication, the exercise ejection fraction increased signifi- 
cantly in both groups (Fig. 1). By contrast, the change in 
ejection fraction from rest to exercise improved significantly 
with medication (+6 percentage points, p = 0.0000; 95% 
confidence interval [CI] 4 to 9; Fig. 2) only in the event-free 
group (with cardioprotection), which showed a mean in- 
crease of 2 percentage points in ejection fraction with 
exercise, whereas the group with adverse vents (failure of 
cardioprotection) showed a persistent exercise-induced de- 
crease of 8 percentage points (p = 0.0000; 95% CI 6 to 15; 
Table 1). 
Post hoe Kaplan-Meier analysis. Hazard ratios for the best 
receiver operating characteristic utoff points for exercise 
ejection fraction and the change in ejection fraction from rest 
to exercise are shown in Table 2. For each radionuclide index, 
the event-free survival experience was significantly different 
between the two groups stratified by the cutoff point. The 
overall predictive accuracy of these prognostic riteria for 
adverse outcome ranged from 64% to 72%; performance was 
considerably better in correctly classifying patients without 
adverse vents (85% to 93% of cases) than patients with events 
(33% to 44% of cases) (Table 3). 
Figure 1. Effect of medication (Rx) on exercise jection fraction 
(LVEF) in groups with and without adverse events. 
Exercise LVEF (%) 
eo No Events 
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Figure 2. Effect of medication (Rx) on the change inejection fraction 
from rest o exercise (ALVEF) in groups with and without adverse 
events. 
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Table 2. Best Receiver Operating Characteristic Cutoff Points and 
Hazard Ratios 
Hazard 
Ratio 95% CI 
Decrease in LVEF 
Without medication >-7 f/, 3.3 1.4-7.6 
With medication ->2% 6.0 2.1-11.4 
Exercise LVEF 
Without medication -<42% 4.8 1.6- 8.6 
With medication -<47~ 2.2 0.95-5.2 
Abbreviations as in Table 1. 
Area under the receiver operating characteristic curves. 
Figure 3 shows that he change in ejection fraction from rest to 
exercise with medication provided the best discrimination 
between the event-free group and the group with events, 
followed by exercise jection fraction without medication (p < 
0.01), the change in ejection fraction from rest to exercise 
without medication (p < 0.01) and, lastly, exercise jection 
fraction with medication (p < 0.01). 
Multiple regression analysis. In Cox proportional hazards 
regression analysis, the first variable to be entered was the 
change in ejection fraction from rest to exercise with medica- 
tion (p = 0.0001), followed by exercise work load (p = 0.0399) 
(Table 4). In this postangiography study group from which 
patients with the worst prognostic indicators had already been 
excluded, no other variables including positive exercise ECG 
results made a significant independent contribution to event- 
free survival. Exercise ejection fraction without medication 
(p = 0.0447) and the change in ejection fraction from rest to 
exercise without medication (p = 0.0068) made a significant 
contribution when forced into a logistic regression model. 
However, both variables became nonsignificant with the entry 
of the change in ejection fraction from rest to exercise with 
medication (p = 0.0013) (Table 4). Exercise ejection fraction 
with medication did not meet the 5% significance level for 
entry into the model. 
Discuss ion  
Prognostic importance of ejection fraction. The traditional 
determinants of prognosis in coronary disease are coronary 
anatomy, left ventricular function and inducibility of myocar- 
dial ischemia (6). How these relate to the propensity o plaque 
Sensitivity 
."" AUC 
. . . .  o.  
I1"/  _ . "  - . -  tV tF . ,  0..7 
~1 J."" - - -  ¢~ LVEF off Rx 0.67 
. . - .  0,2  
0 
1-Specificity 
Figure 3. Area under the receiver operating characteristic curves 
(AUC). Ex = exercise. Other abbreviations as in Figure 2. 
rupture is not clear, although extensive coronary obstructive 
lesions, inducible ischemia nd left ventricular dysfunction due 
to previous infarction may be markers of the widespread 
presence of lipid-rich macrophage-laden plaques. One nonin- 
vasive test that allows direct quantification f both left ventric- 
ular systolic function and exercise-induced ischemia is radio- 
nuclide ventriculography. With this method, ejection fraction 
at peak exercise is probably the most important predictor of 
cardiovascular mortality (7-10), whereas the change in ejection 
fraction from rest to exercise may better describe the risk of 
ischemic morbidity and ischemia-related mortality (7,11-13). 
Therefore, although the risk of death may be similar in two 
patients with an exercise jection fraction of 35%, it is possible 
that the patient whose ejection fraction decreases from 55% is 
at greater isk of ischemia-related vents than is the patient 
whose ejection fraction increases from 30%. 
Effect of medication on ejection fraction. Given the prog- 
nostic importance ofthe ejection fraction response to exercise, 
can its modification by medication allow some assessment of
cardioprotective efficacy and so be exploited to optimize the 
management of coronary disease? The variable effect of anti- 
ischemic drugs on left ventricular function in patients with 
coronary artery disease is well described (14-18). However, 
Table 3. Predictive Performance of Prognostic Left Ventricular Ejection Fraction Criteria 
Sensitivity Specificity Positive Predictive Negative Predictive Predictive 
(¢'~) (%) Value (%) Value (%) Accuracy (%) 
Exercise LVEF 
Without medication 81 62 37 92 66 
With medication 59 66 33 85 64 
ALVEF 
Without medication 71 65 36 89 66 
With medication 82 70 44 93 72 
Abbreviations as in Table 1. 
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Table 4. Multiple Regression Analyses 
Regression Risk p 
Variable* Coefficient SE Ratio Value 
Cox regression 
ALVEF with medication 0.1155 0.0251 0.891 0.0001 
Work load with medication - 0.0027 0.0013 0.997 0.0399 
Logistic regression 
Exercise LVEE without medication? 0.0478 0.0248 1.049 0.0545 
~LVEF without medicationt 0.0406 0.0373 1.041 0.2766 
~LVEF with medication 0.1155 0.0251 0.891 0.0001 
*No additional variables met 0.05 level for entry into model, tForced into the model. Abbreviations as in Table 1. 
the present study examined the prognostic mplications of the 
effect of clinically effective background medical treatment 
(rather than individual classes, combinations ordoses of drugs) 
on ejection fraction indexes as measured by radionuclide 
ventriculography. It also differs from previous investigations in 
that testing both without and with medication was performed 
systematically in each patient. Unlike other investigators, we 
have not assumed that because anti-ischemic medication may 
diminish the inducibility of ischemia, it degrades the potential 
value of stress testing for risk estimation. Indeed, this study 
offers the alternative perspective: An improved or preserved 
ejection fraction response to exercise during testing with 
medication implies some measure of protection from risk. 
Study limitations. This nonrandomized study focused on a 
group of patients who, after consideration f all the usual risk 
factors, including age and abnormal exercise test results, were 
selected to continue with medical therapy initially for the 
following reasons. 1) At the time of coronary angiography, 
their symptoms were adequately controlled, and 2) although 
they had coronary disease that could be treated by revascular- 
ization, such treatment was not deemed mandatory solely on 
prognostic grounds. The results are therefore applicable only 
to such patients. 
It is not surprising that traditional risk indicators may no 
longer have any significant independent impact on event-free 
survival in a group from which the highest risk patients were 
already excluded by virtue of referral for early revasculariza- 
tion. Nevertheless, patients initially treated medically remain 
at risk for adverse vents, including the need for revascular- 
ization because of recurrence of troublesome symptoms. In- 
deed, 23 of 102 such patients had an adverse vent (cardiac 
death or myocardial infarction in 5) including crossover to 
revascularization ver a 20-month period; most (20 of 23) of 
these vents occurred within I year after angiography. The aim 
of this study was to see whether the concept of cardioprotec- 
tion based on ejection fraction could be tested and thus applied 
clinically to refine prognostic assessment in such a postangiog- 
raphy group in which conventional risk factors may no longer 
fully apply. 
Clinical implications. Improvement in exercise ejection 
fraction may imply reduction in risk of cardiovascular mortal- 
ity; however, apersistent exercise-induced decrease inejection 
fraction despite medication may indicate continuing risk of 
ischemia-related events. Mortality due to critically reduced 
myocardial reserve may not be wholly amenable to prevention 
by revascularization, whereas morbidity and mortality related 
to inducible ischemia suggest a situation with potential for 
improvement. In this study biased toward nonfatal adverse 
events, the best discrimination between the groups with and 
without events was provided by the change in ejection fraction 
from rest to exercise with medication (Fig. 3), suggesting that 
this index is the most useful clinical measure of cardioprotec- 
tion from an adverse cardiac prognosis. In the post hoc best 
case analysis, this variable correctly identifies seven more 
patients with adverse outcome than does exercise ejection 
fraction without medication for every 100 patients tested 
(Table 3). Furthermore, the results of multivariate analyses 
favor testing only with medication, with no additional or 
independent prognostic value from testing without medication. 
In this study group, the results imply that a patient aking 
medication who has an exercise-induced decrease in ejection 
fraction ->2 percentage points has up to a 44% chance of 
experiencing within 20 months an adverse vent hat in 22% (5 
of 23) of cases will be cardiac death or nonfatal myocardial 
infarction. Such patients may benefit from discussion of the 
options of early revascularization r watchful waiting, although 
the latter strategy mandates rapid access to revascularization 
or repeat angiography. By contrast, if the change in ejection 
fraction from rest to exercise with medication is <2 percentage 
points, the probability of an event during 20 months is only 7%. 
The results also indicate that when the ejection fraction 
response to exercise is improved uring radionuclide ventricu- 
lography performed with medication, it occurs largely by an 
increase in the absolute exercise ejection fraction, with no 
significant change in rest ejection fraction. This observation 
suggests that the cardioprotectiveness of anti-ischemic medi- 
cation may be measured simply and noninvasively by its effect 
on prognostic ejection fraction indexes, and it raises the 
possibility that medical treatment can be titrated to achieve 
optimal cardioprotection in individual patients. 
Randomized study is necessary to confirm whether such 
objective assessment ofcardioprotection adds a new dimension 
to risk stratification for rationalizing the allocation of invasive 
resources and for optimizing the management of patients who 
have neither disease that seems immediately ife-threatening 
nor angina that is severely limiting. 
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